The role of statins as therapeutic agents in cancer
| Autor: | Jan Strnadel, Henrieta Škovierová, Janka Sopková, Erika Halasova, Eva Vidomanová |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Male Physiology Angiogenesis Carcinogenesis Biophysics Mevalonic Acid Reductase medicine.disease_cause Models Biological Metastasis 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Neoplasms medicine Humans Evidence-Based Medicine Dose-Response Relationship Drug business.industry Cell growth Cholesterol nutritional and metabolic diseases Cancer General Medicine medicine.disease 030104 developmental biology Treatment Outcome chemistry 030220 oncology & carcinogenesis Cancer cell Cancer research lipids (amino acids peptides and proteins) Female Hydroxymethylglutaryl-CoA Reductase Inhibitors business |
| Zdroj: | General physiology and biophysics. 36(5) |
| ISSN: | 0231-5882 |
| Popis: | Statins are the inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. This enzyme catalyzes conversion of HMG-CoA to mevalonate, which are the intermediates in cholesterol biosynthetic pathway. Statins also play an important role in carcinogenesis, because they are able to affect the cancer cell metabolism. Their effect has been observed in several cellular processes, such as angiogenesis, metastasis, apoptosis and cell proliferation. However, these effects are highly dependent on type of cancer and individual statins vary in their antitumor potential. This review summarizes the recent epidemiological evidence and preclinical studies that showed effects of all clinically used statins in vitro and in vivo. We also consider the results of different observational and retrospective studies focused on association among statins and cancer risk which are still under open discussion. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|